Compare · HOWL vs JNJ
HOWL vs JNJ
Side-by-side comparison of Werewolf Therapeutics Inc. (HOWL) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HOWL and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $579.83B, about 31315.9x HOWL ($18.5M).
- Over the past year, HOWL is down 68.1% and JNJ is up 53.4% - JNJ leads by 121.4 points.
- HOWL has been more active in the news (19 items in the past 4 weeks vs 14 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 6 for HOWL).
- Company
- Werewolf Therapeutics Inc.
- Johnson & Johnson
- Price
- $0.39-0.28%
- $240.84+1.06%
- Market cap
- $18.5M
- $579.83B
- 1M return
- -34.32%
- +4.51%
- 1Y return
- -68.07%
- +53.35%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 19
- 14
- Recent ratings
- 6
- 25
Werewolf Therapeutics Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest HOWL
- Large owner Ra Capital Management, L.P. sold $253,569 worth of shares (678,226 units at $0.37) (SEC Form 4)
- Director Evnin Luke sold $28,463 worth of shares (76,928 units at $0.37) as part of a pre-agreed trading plan (SEC Form 4)
- Director Evnin Luke sold $43,029 worth of shares (105,565 units at $0.41) as part of a pre-agreed trading plan (SEC Form 4)
- Director Evnin Luke sold $63,628 worth of shares (139,803 units at $0.46) as part of a pre-agreed trading plan (SEC Form 4)
- Director Evnin Luke sold $66,200 worth of shares (141,106 units at $0.47) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Werewolf Therapeutics Inc.
- SEC Form 144 filed by Werewolf Therapeutics Inc.
- SEC Form 144 filed by Werewolf Therapeutics Inc.
- SEC Form 144 filed by Werewolf Therapeutics Inc.
- SEC Form 144 filed by Werewolf Therapeutics Inc.
Latest JNJ
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer